Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04730635 · ClinicalTrials.gov registry record · Phase 1
Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT04730635 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 44 participants.
The verdict
NCT04730635, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among participants with mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD). The primary study hypothesis is that the average percentage of correct responses on one card learning (OCL) task will be ≥2 percentage points in participants receiving donepezil compared with participants receiving placebo.
Interventions
- DRUG Placebo
- DRUG Donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-03-23 |
| Est. Completion | 2023-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04730635
The ClinicalTrials.gov registry entry for NCT04730635 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04730635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04730635 about?
NCT04730635 is a clinical study titled "Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)". The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among participants with mild cognitive impairment (MCI) or mild Alzheimer's Disea...
What is the current status of trial NCT04730635?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2021-03-23. Estimated completion is 2023-02-06.
What interventions are being tested in trial NCT04730635?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG).
Who is sponsoring clinical trial NCT04730635?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.